The IPR waiver would allow all countries to choose to neither grant nor enforce patents and other IPRs related to COVID-19 drugs, vaccines, diagnostics and other technologies for the duration of the pandemic until global herd immunity is achieved. This move harkens back 20 years to the HIV/AIDS epidemic, when affordable generic HIV drugs, made in countries where patents did not block production, began saving millions of people’s lives.
